Replies to post #76769 on Biotech Values

[DewDiligence]

DVAX: So Heplisav is more efficacious than Engerix-B, the licensed vaccine, requires fewer doses, and has similar side effects, including the one case of vasculitis. Does anyone else find it absurd that, given these facts, Heplisav would be on a clinical hold while the approved product remains on the market?

Investors clearly don’t have the whole story on this story.

And do you think Heplisav can eventually make it to market given what appears to be an advantage in efficacy and dosing?

Given the clinical hold and the busted partnership agreement, it looks like a long shot.